This method likely allows for the presentation of MHC-II-restricted tumor antigens that may not normally be presented to CD4+ T cells, and this could be responsible for eliciting the cytotoxic CD4+ T cells in this treatment paradigm (37). Here, CD4 is linked to neoplasm.